The association between the acute-phase reactant proteins (APRPs) and cancer has long been established. There have been numerous reports correlating altered levels of various APRPs with different types of cancers. However, researchers are often quick to dismiss the use of these APRPs as potential biomarkers for the diagnosis and monitoring of cancer because alterations in APRP concentrations are observed in a wide range of diseases. Recent progress in proteomics studies which profiled the serum proteins of cancer patients and those of normal individuals indicated that the altered APRP expressions were different for distinct types, subtypes, and even stages of cancer. Interestingly, these data are in agreement with those observed earlier using immunochemical and biochemical assays. In view of this compelling association of different patterns of APRPs with various types of cancers and in an apparent shift of paradigm, we present in this review some indications that APRP fingerprinting may be used as complementary cancer biomarkers.
TillettW.S., FrancisT.Jr.. Serological reactions in pneumonia with a non-protein somatic fraction of Pneumococcus.J Exp Med1930; 52: 561–71.
2.
AbernethyT.J., AveryO.T.The occurrence during acute infections of a protein not normally present in the blood: I. Distribution of the reactive protein in patients' sera and the effect of calcium on the flocculation reaction with C-polysaccharide of Pneumococcus.J Exp Med1941; 73: 173–82.
3.
HiramatsuS., KojimaJ., OkadaT.T., InaiS., OhmoriK.The serum protein profile in chronic hepatitis, cirrhosis and liver cancer.Acta Hepatogastroenterol (Stuttg)1976; 23: 177–82.
4.
ThompsonD., BirdH.A.Acute phase response. In: IsenbergD.A., MaddisonP.J., WooP., GlassD., BreedveldF.C., eds. Oxford textbook of rheumatology.3rd ed.Oxford: Oxford University Press2004; 473–8.
5.
GruysE., ToussaintM.J., NiewoldT.A., KoopmansS.J., van DijkE., MeloenR.H.Monitoring health by values of acute phase proteins.Acta Histochem2006; 108: 229–32.
6.
KushnerI., GanapathiM., SchultzD.The acute phase response is mediated by heterogeneous mechanisms.Ann N Y Acad Sci1989; 557: 19–29; discussion: 30.
7.
MackiewiczA.Acute phase proteins and transformed cells.Int Rev Cytol1997; 170: 225–300.
8.
KushnerI., MackiewiczA.Acute phase proteins as disease markers.Dis Markers1987; 5: 1–11.
9.
JenneD.E., TschoppJ.Molecular structure and functional characterization of a human complement cytolysis inhibitor found in blood and seminal plasma: identity to sulfated glycoprotein 2, a constituent of rat testis fluid.Proc Natl Acad Sci U S A1989; 86: 7123–7.
10.
KirszbaumL., SharpeJ.A., MurphyB.Molecular cloning and characterization of the novel, human complement-associated protein, SP-40,40: a link between the complement and reproductive systems.EMBO J1989; 8: 711–8.
11.
TrougakosI.P., GonosE.S.Clusterin/apolipoprotein J in human aging and cancer.Int J Biochem Cell Biol2002; 34: 1430–48.
12.
VolanakisJ.E.Acute phase proteins in rheumatic disease. In: KoopmanW.J., ed. Arthritis and allied conditions: a textbook of rheumatology.13 ed.Baltimore: Williams & Wilkins1997; 505–14.
13.
GabayC., KushnerI.Acute-phase proteins and other systemic responses to inflammation.N Engl J Med1999; 340: 448–54.
14.
BankU., AnsorgeS.More than destructive: neutrophil-derived serine proteases in cytokine bioactivity control.J Leukoc Biol2001; 69: 197–206.
15.
CooperE.H., WardA.M.Acute phase reactant proteins as aids to monitoring disease.Invest Cell Pathol1979; 2: 293–301.
16.
SamokyszynV.M., MillerD.M., ReifD.W., AustS.D.Inhibition of superoxide and ferritin-dependent lipid peroxidation by ceruloplasmin.J Biol Chem1989; 264: 21–6.
17.
GutteridgeJ.M., SmithA.Antioxidant protection by haemopexin of haem-stimulated lipid peroxidation.Biochem J1988; 256: 861–5.
18.
KikuchiT., AbeT., YaekashiwaM.Secretory leukoprotease inhibitor augments hepatocyte growth factor production in human lung fibroblasts.Am J Respir Cell Mol Biol2000; 23: 364–70.
19.
DabbaghK., LaurentG.J., ShockA., LeoniP., PapakrivopoulouJ., ChambersR.C.Alpha-1-antitrypsin stimulates fibroblast proliferation and procollagen production and activates classical MAP kinase signalling pathways.J Cell Physiol2001; 186: 73–81.
20.
GraziadeiI., GagglS., KaserbacherR., BraunsteinerH., VogelW.The acute-phase protein alpha 1-antitrypsin inhibits growth and proliferation of human early erythroid progenitor cells (burst-forming units-erythroid) and of human erythroleukemic cells (K562) in vitro by interfering with transferrin iron uptake.Blood1994; 83: 260–8.
21.
BandaM.J., RiceA.G., GriffinG.L., SeniorR.M.The inhibitory complex of human alpha 1-proteinase inhibitor and human leukocyte elastase is a neutrophil chemoattractant.J Exp Med1988; 167: 1608–15.
22.
JoslinG., FallonR.J., BullockJ., AdamsS.P., PerlmutterD.H.The SEC receptor recognizes a pentapeptide neodomain of alpha 1-antitrypsin-protease complexes.J Biol Chem1991; 266: 11282–8.
23.
CoussensL.M., WerbZ.Inflammation and cancer.Nature2002; 420: 860–7.
BalkwillF., MantovaniA.Inflammation and cancer: back to Virchow?Lancet2001; 357: 539–45.
26.
KuperH., AdamiH.O., TrichopoulosD.Infections as a major preventable cause of human cancer.J Intern Med2000; 248: 171–83.
27.
WahlL.M., KleinmanH.K.Tumor-associated macrophages as targets for cancer therapy.J Natl Cancer Inst1998; 90: 1583–4.
28.
YamanishiY., BoyleD.L., RosengrenS., GreenD.R., ZvaiflerN.J., FiresteinG.S.Regional analysis of p53 mutations in rheumatoid arthritis synovium.Proc Natl Acad Sci U S A2002; 99: 10025–30.
29.
AokiY., YarchoanR., BraunJ., IwamotoA., TosatoG.Viral and cellular cytokines in AIDS-related malignant lymphomatous effusions.Blood2000; 96: 1599–601.
30.
TrentinL., CeruttiA., ZambelloR.Interleukin-15 promotes the growth of leukemic cells of patients with B-cell chronic lymphoproliferative disorders.Blood1996; 87: 3327–35.
31.
BernackaK., Kuryliszyn-MoskalA., SierakowskiS.The levels of alpha 1-antitrypsin and alpha 1-antichymotrypsin in the sera of patients with gastrointestinal cancers during diagnosis.Cancer1988; 62: 1188–93.
32.
StamatiadisA.P., St ToumanidouM., VyssoulisG.P., ManourasA.J., ApostolidisN.S.Value of serum acute-phase reactant proteins and carcinoembryonic antigen in the preoperative staging of colorectal cancer. A multivariate analysis.Cancer1990; 65: 2055–7.
33.
SolakidiS., DessyprisA., StathopoulosG.P., AndroulakisG., SekerisC.E.Tumour-associated trypsin inhibitor, carcinoembryonic antigen and acute-phase reactant proteins CRP and alpha1-antitrypsin in patients with gastrointestinal malignancies.Clin Biochem2004; 37: 56–60.
BhattacharyyaJ., ChaudhuriL.Alpha 1-antitrypsin: a possible tool for diagnosis of cervical cancer.Biochem Med Metab Biol1990; 43: 243–5.
36.
NasulewiczA., MazurA., OpolskiA.Role of copper in tumour angiogenesis–clinical implications.J Trace Elem Med Biol2004; 18: 1–8.
37.
ItakuraJ., IshiwataT., FriessH.Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression.Clin Cancer Res1997; 3: 1309–16.
38.
ZelvyteI., WallmarkA., PiitulainenE., WestinU., JanciauskieneS.Increased plasma levels of serine proteinase inhibitors in lung cancer patients.Anticancer Res2004; 24: 241–7.
39.
El-AkawiZ.J., Al-HindawiF.K., BashirN.A.Alpha-1 antitrypsin (alpha1-AT) plasma levels in lung, prostate and breast cancer patients.Neuro Endocrinol Lett2008; 29: 482–4.
40.
MerliniG., PerfettiV., GobbiP.G.Acute phase proteins and prognosis in multiple myeloma.Br J Haematol1993; 83: 595–601.
41.
KoeblH., TatraG., BieglmayerC.A comparative study of immunosuppressive acidic protein (IAP), CA 125 and acute-phase proteins as parameters for ovarian cancer monitoring.Neoplasma1988; 35: 215–20.
42.
BuamahP.K., SkillenA.W.Concentrations of protease and anti-protease in serum of patients with pancreatic cancer.Clin Chem1985; 31: 876–7.
43.
TountasY., SparosL., TheodoropoulosC., TrichopoulosD.Alpha 1-antitrypsin and cancer of the pancreas.Digestion1985; 31: 37–40.
44.
KuvibidilaS., RayfordW.Correlation between serum prostate-specific antigen and alpha-1-antitrypsin in men without and with prostate cancer.J Lab Clin Med2006; 147: 174–81.
45.
KalabayL., JakabL., ProhaszkaZ.Human fetuin/alpha2HS-glycoprotein level as a novel indicator of liver cell function and short-term mortality in patients with liver cirrhosis and liver cancer.Eur J Gastroenterol Hepatol2002; 14: 389–94.
46.
StejskalD., FialaR.R.Evaluation of serum and urine clusterin as a potential tumor marker for urinary bladder cancer.Neoplasma2006; 53: 343–6.
47.
KirchheimerJ.C., KolblH., TatraG., BinderB.R.Relationship between plasma levels of components of the fibrinolytic system and acute-phase reactants in patients with uterine malignancies.Eur J Clin Invest1990; 20: 79–84.
48.
ArumanayagamM., WongF.W., RogersM., SwaminathanR.Serum ceruloplasmin, plasma copper concentration and copper to ceruloplasmin ratio in cervical carcinoma.Gynecol Obstet Invest1993; 35: 175–8.
49.
GundogduM., KayaH., GulcinI.Oxidase activity of ceruloplasmin and some acute phase reactant and trace element concentrations in serum of patients with chronic lymphocytic leukemia.Scott Med J2007; 52: 24–7.
50.
TsavarisN., KosmasC., KopteridesP.Retinol-binding protein, acute phase reactants and Helicobacter pylori infection in patients with gastric adenocarcinoma.World J Gastroenterol2005; 11: 7174–8.
51.
BozA., EvliyaogluO., YildirimM., ErkanN., KaracaB.The value of serum zinc, copper, ceruloplasmin levels in patients with gastrointestinal tract cancers.Turk J Gastroenterol2005; 16: 81–4.
52.
AgroyannisB., DalamangasA., DardouphasK.Serum transferrin and ceruloplasmin in patients with cancer of the gastrointestinal and other systems.Anticancer Res1994; 14: 2201–3.
53.
PejovicM., DjordjevicV., IgnjatovicI., StamenicT., StefanovicV.Serum levels of some acute phase proteins in kidney and urinary tract urothelial cancers.Int Urol Nephrol1997; 29: 427–32.
54.
EsmeH., CemekM., SezerM.High levels of oxidative stress in patients with advanced lung cancer.Respirology2008; 13: 112–6.
55.
Ros-BullonM.R., Sanchez-PedrenoP., Martinez-LiarteJ.H.Serum ceruloplasmin in melanoma patients.Anticancer Res2001; 21: 629–32.
56.
Senra VarelaA., Lopez SaezJ.J., Quintela SenraD.Serum ceruloplasmin as a diagnostic marker of cancer.Cancer Lett1997; 121: 139–45.
57.
Avall LundqvistE., BladE., XiaoL., SjovallK., EnerothP.Pretreatment serum levels of C-reactive protein, alpha 1-antitrypsin, haptoglobin, alpha 1-acid glycoprotein and tissue polypeptide antigen in cervical carcinoma.Eur J Gynaecol Oncol1991; 12: 375–83.
58.
ZhaoJ., PatwaT.H., QiuW.Glycoprotein microarrays with multi-lectin detection: unique lectin binding patterns as a tool for classifying normal, chronic pancreatitis and pancreatic cancer sera.J Proteome Res2007; 6: 1864–74.
59.
RoeiseO., SivertsenS., RuudT.E., BoumaB.N., StadaasJ.O., AasenA.O.Studies on components of the contact phase system in patients with advanced gastrointestinal cancer.Cancer1990; 65: 1355–9.
60.
SrinivasP.R., WagnerA.S., ReddyL.V.Serum alpha 2-HS-glycoprotein is an inhibitor of the human insulin receptor at the tyrosine kinase level.Mol Endocrinol1993; 7: 1445–55.
61.
KalabayL., ChavinK., LebretonJ.P., RobinsonK.A., BuseM.G., ArnaudP.Human recombinant alpha 2-HS glycoprotein is produced in insect cells as a full length inhibitor of the insulin receptor tyrosine kinase.Horm Metab Res1998; 30: 1–6.
62.
RaghothamaC., AkhileshP.Quantitative proteomics for identification of cancer biomarkers.Proteomics - Clinical Applications2007; 1: 1080–9.
63.
SimpsonR.J., BernhardO.K., GreeningD.W., MoritzR.L.Proteomics-driven cancer biomarker discovery: looking to the future.Curr Opin Chem Biol2008; 12: 72–7.
64.
ChoW.C.Contribution of oncoproteomics to cancer biomarker discovery.Mol Cancer2007; 6: 25.
65.
AdkinsJ.N., VarnumS.M., AuberryK.J.Toward a human blood serum proteome: analysis by multidimensional separation coupled with mass spectrometry.Mol Cell Proteomics2002; 1: 947–55.
66.
WangY.Y., ChengP., ChanD.W.A simple affinity spin tube filter method for removing high-abundant common proteins or enriching low-abundant biomarkers for serum proteomic analysis.Proteomics2003; 3: 243–8.
67.
PieperR., GatlinC.L., MakuskyA.J.The human serum proteome: display of nearly 3700 chromatographically separated protein spots on two-dimensional electrophoresis gels and identification of 325 distinct proteins.Proteomics2003; 3: 1345–64.
68.
AhmedN., BarkerG., OlivaK.T.Proteomic-based identification of haptoglobin-1 precursor as a novel circulating biomarker of ovarian cancer.Br J Cancer2004; 91: 129–40.
69.
GrangerJ., SiddiquiJ., CopelandS., RemickD.Albumin depletion of human plasma also removes low abundance proteins including the cytokines.Proteomics2005; 5: 4713–8.
HamritaB., ChahedK., TrimecheM.Proteomics-based identification of alpha1-antitrypsin and haptoglobin precursors as novel serum markers in infiltrating ductal breast carcinomas.Clin Chim Acta2009; 404: 111–8.
72.
WardD.G., SuggettN., ChengY.Identification of serum biomarkers for colon cancer by proteomic analysis.Br J Cancer2006; 94: 1898–905.
73.
PatzE.F.Jr., CampaM.J., GottlinE.B., KusmartsevaI., GuanX.R., HerndonJE2nd. Panel of serum biomarkers for the diagnosis of lung cancer.J Clin Oncol2007; 25: 5578–83.
74.
SunZ.L., ZhuY., WangF.Q.Serum proteomic-based analysis of pancreatic carcinoma for the identification of potential cancer biomarkers.Biochim Biophys Acta2007; 1774: 764–71.
75.
KoomenJ.M., ShihL.N., CoombesK.R.Plasma protein profiling for diagnosis of pancreatic cancer reveals the presence of host response proteins.Clin Cancer Res2005; 11: 1110–8.
76.
YuK.H., RustgiA.K., BlairI.A.Characterization of proteins in human pancreatic cancer serum using differential gel electrophoresis and tandem mass spectrometry.J Proteome Res2005; 4: 1742–51.
77.
KwakJ.Y., MaT.Z., YooM.J.The comparative analysis of serum proteomes for the discovery of biomarkers for acute myeloid leukemia.Exp Hematol2004; 32: 836–42.
78.
DowlingP., O'DriscollL., MeleadyP.2-D difference gel electrophoresis of the lung squamous cell carcinoma versus normal sera demonstrates consistent alterations in the levels of ten specific proteins.Electrophoresis2007; 28: 4302–10.
79.
BloomstonM., ZhouJ.X., RosemurgyA.S., FrankelW., Muro-CachoC.A., YeatmanT.J.Fibrinogen gamma overexpression in pancreatic cancer identified by large-scale proteomic analysis of serum samples.Cancer Res2006; 66: 2592–9.
80.
Rodriguez-PineiroA.M., de la CadenaM.P., Lopez-SacoA., Rodriguez-BerrocalF.J.Differential expression of serum clusterin isoforms in colorectal cancer.Mol Cell Proteomics2006; 5: 1647–57.
81.
ZhangL.Y., YingW.T., MaoY.S.Loss of clusterin both in serum and tissue correlates with the tumorigenesis of esophageal squamous cell carcinoma via proteomics approaches.World J Gastroenterol2003; 9: 650–4.
82.
HanasJ.S., HockerJ.R., CheungJ.Y.Biomarker identification in human pancreatic cancer sera.Pancreas2008; 36: 61–9.
83.
HuangH.L., StasykT., MorandellS.Biomarker discovery in breast cancer serum using 2-D differential gel electrophoresis/MALDI-TOF/TOF and data validation by routine clinical assays.Electrophoresis2006; 27: 1641–50.
84.
ChenC.B., SuY.C., HuangT.T.Differentially expressed serum haptoglobin alpha chain isoforms with potential application for diagnosis of head and neck cancer.Clin Chim Acta2008; 398: 48–52.
85.
AngI.L., PoonT.C., LaiP.B.Study of serum haptoglobin and its glycoforms in the diagnosis of hepatocellular carcinoma: a glycoproteomic approach.J Proteome Res2006; 5: 2691–700.
86.
MacielC.M., JunqueiraM., PaschoalM.E.Differential proteomic serum pattern of low molecular weight proteins expressed by adenocarcinoma lung cancer patients.J Exp Ther Oncol2005; 5: 31–8.
87.
YeB., CramerD.W., SkatesS.J.Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry.Clin Cancer Res2003; 9: 2904–11.
88.
HeoS.H., LeeS.J., RyooH.M., ParkJ.Y., ChoJ.Y.Identification of putative serum glycoprotein biomarkers for human lung adenocarcinoma by multilectin affinity chromatography and LC-MS/MS.Proteomics2007; 7: 4292–302.
89.
DengR., LuZ., ChenY., ZhouL., LuX.Plasma proteomic analysis of pancreatic cancer by 2-dimensional gel electrophoresis.Pancreas2007; 34: 310–7.
90.
KakisakaT., KondoT., OkanoT.Plasma proteomics of pancreatic cancer patients by multi-dimensional liquid chromatography and two-dimensional difference gel electrophoresis (2D-DIGE): up-regulation of leucine-rich alpha-2–glycoprotein in pancreatic cancer.J Chromatogr B Analyt Technol Biomed Life Sci2007; 852: 257–67.
91.
BondarO.P., BarnidgeD.R., KleeE.W., DavisB.J., KleeG.G.LC-MS/MS quantification of Zn-alpha2 glycoprotein: a potential serum biomarker for prostate cancer.Clin Chem2007; 53: 673–8.
92.
DoustjalaliS.R., YusofR., YipC.H., LooiL.M., PillayB., HashimO.H.Aberrant expression of acute-phase reactant proteins in sera and breast lesions of patients with malignant and benign breast tumors.Electrophoresis2004; 25: 2392–401.
93.
DoustjalaliS.R., YusofR., GovindasamyG.K., BustamA.Z., PillayB., HashimO.H.Patients with nasopharyngeal carcinoma demonstrate enhanced serum and tissue ceruloplasmin expression.J Med Invest2006; 53: 20–8.
94.
Abdul-RahmanP.S., LimB.K., HashimO.H.Expression of high-abundance proteins in sera of patients with endometrial and cervical cancers: analysis using 2-DE with silver staining and lectin detection methods.Electrophoresis2007; 28: 1989–96.
95.
ChenY., LimB.K., PehS.C., Abdul-RahmanP.S., HashimO.H.Profiling of serum and tissue high abundance acute-phase proteins of patients with epithelial and germ line ovarian carcinoma.Proteome Sci2008; 6: 20.
96.
LangloisM.R., DelangheJ.R.Biological and clinical significance of haptoglobin polymorphism in humans.Clin Chem1996; 42: 1589–600.
